130 results
8-K
EX-99.1
ZVRA
Zevra Therapeutics Inc
8 May 24
Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
7:54am
. “With a solid balance sheet, we are focused on creating long-term value for shareholders by executing against our plan of becoming a leading rare disease … , caregivers and physicians.
In April 2024, the Company presented new long-term, real-world data from the expanded access program (EAP: NCT04316637
DEFA14A
ZVRA
Zevra Therapeutics Inc
29 Apr 24
Additional proxy soliciting materials
7:49am
long-term incentives that are fully aligned with stockholders' interests in the pursuit of long-term value creation.
We’ve Made Significant Progress … restarted recruitment of the ongoing Phase 3 trial, which is a long-term event-driven trial design, and believe that celiprolol could address significant
424B3
ZVRA
Zevra Therapeutics Inc
10 Apr 24
Prospectus supplement
4:23pm
pipeline could be accretive to our value proposition by potentially adding new clinical data catalysts and have the potential to create incremental long … -term value for stockholders. In addition, we believe that a multi-channel development program with several product candidates addressing various rare
8-K
EX-99.1
rh1j9w
28 Mar 24
Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
4:35pm
8-K/A
EX-99.3
nousn9ghpueydqg2e ri
5 Feb 24
Financial Statements and Exhibits
12:00am
8-K
EX-99.1
l8mr7vbxbhhyhhtakcr
27 Dec 23
Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug Administration
7:48am
424B5
ur0lgrj53 gpwf3rd
21 Nov 23
Prospectus supplement for primary offering
7:40pm
8-K
EX-99.1
0je xvol1kweu
20 Nov 23
Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company
7:36am
8-K
EX-10.1
dw2debg
20 Nov 23
Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company
7:36am
8-K
EX-99.1
4y4kr25q75vjn4
7 Nov 23
Zevra Therapeutics Reports Corporate Updates and Third Quarter 2023 Financial
7:25am
8-K
EX-10.1
k9uidhvqg3kb739tfy
10 Oct 23
Departure of Directors or Certain Officers
5:12pm
424B3
rvypi 1ou9nzinxgp8em
10 Oct 23
Prospectus supplement
5:07pm
S-4/A
yxp112
6 Oct 23
Registration of securities issued in business combination transactions (amended)
4:06pm
S-4
qichknje1 sw
28 Sep 23
Registration of securities issued in business combination transactions
9:25pm